Study§ | Intervention | Primary; secondary CV outcomes§§ | Events (n) treatment | Events (%) treatment | Rate (%.year-1) treatment | Events (n) control | Events (%) control | Rate (%.year-1) control | HR | 95 % CI for HR | P |
---|---|---|---|---|---|---|---|---|---|---|---|
4D | statin | C; D + J | 226 | 36.5 | 9.13 | 243 | 38.2 | 9.55 | 0.96 | 0.77-1.1 | 0.37 |
4S | statin | A | 182 | 8.2 | 1.52 | 256 | 11.5 | 2.13 | 0.71 | 0.58-0.85 | 0.0003 |
 diabetes substudy | statin | A | 15 | 14.3 | 2.65 | 24 | 24.7 | 4.58 | 0.58 | NR | 0.087 |
ACCORD-Lipid | fibrate | C; J + D | 291 | 10.5 | 2.24 | 310 | 11.3 | 2.40 | 0.93 | 0.79-1.08 | 0.32 |
ADDITION-Europe | statin/other | B; D + J + M + Z | 121 | 7.2 | 1.36 | 117 | 8.5 | 1.60 | 0.85 | 0.65-1.05 | 0.12 |
AFCAPS/TexCAPS | statin | C; E | 116 | 3.5 | 0.68 | 183 | 5.5 | 1.07 | 0.63 | 0.50-0.79 | <0.001 |
AIM-HIGH | niacin | C; G + J + H + M | 282 | 16.4 | 5.47 | 274 | 16.2 | 5.39 | 1.02 | 0.87-1.21 | 0.8 |
AleCardio | PPAR-α/γ | C; D + J | 344 | 9.5 | 4.76 | 360 | 10.0 | 4.99 | 0.95 | 0.83-1.11 | 0.57 |
ALERT | statin | C; G + J + M | 112 | 10.7 | 2.09 | 134 | 12.7 | 2.50 | 0.84 | 0.64-1.06 | 0.14 |
ALLHAT-LLT | statin | A | 631 | 12.2 | 2.54 | 641 | 12.4 | 2.58 | 0.99 | 0.89-1.11 | 0.88 |
Alpha-Omega | n-3 fatty acids | B | 336 | 14.0 | 4.11 | 335 | 13.8 | 4.05 | 1.02 | 0.87-1.17 | 0.93 |
ASCOT-LLA | statin | J + G | 100 | 1.9 | 0.59 | 154 | 3.0 | 0.91 | 0.65 | 0.50-0.83 | 0.0005 |
 diabetes substudy | statin | B | 116 | 9.2 | 2.79 | 151 | 11.9 | 3.59 | 0.78 | 0.61-0.98 | 0.04 |
ASPEN | statin | C; D + J + M + O + L | 166 | 13.7 | 3.43 | 180 | 15.0 | 3.75 | 0.91 | 0.73-1.12 | 0.34 |
AURORA | statin | C; J + D | 396 | 28.5 | 7.50 | 408 | 29.5 | 7.76 | 0.97 | 0.84-1.11 | 0.59 |
 diabetes substudy | statin | C; G + J | 85 | 21.9 | 7.82 | 104 | 30.3 | 10.83 | 0.72 | 0.51-0.90 | 0.008 |
BIP | fibrate | C; K + J + P | 211 | 13.6 | 2.20 | 232 | 15.0 | 2.43 | 0.91 | NR | 0.26 |
CARDS | statin | C; H + M + T | 83 | 5.8 | 1.49 | 127 | 9.0 | 2.31 | 0.65 | 0.48-0.83 | 0.001 |
CARE | statin | G + J | 212 | 10.2 | 2.04 | 274 | 13.2 | 2.64 | 0.77 | 0.09-0.36 | 0.003 |
 diabetes substudy | statin | G + J + M | 81 | 28.7 | 5.74 | 112 | 36.8 | 7.37 | 0.78 | NR | <0.0001 |
CDP (clofibrate) | fibrate | A | 281 | 25.5 | 4.11 | 709 | 25.4 | 4.10 | 1.00 | NR | NR |
CDP (niacin) | niacin | A | 273 | 24.4 | 3.93 | 709 | 25.4 | 4.10 | 0.96 | 0.85-1.08 | NR |
dal-OUTCOMES | CETP inhibitor | C; G + J + L + O | 656 | 8.3 | 3.20 | 633 | 8.0 | 3.09 | 1.04 | 0.93-1.16 | 0.52 |
DIS | fibrate | E | 32 | 8.4 | 1.69 | 31 | 8.1 | 1.62 | 1.04 | NR | NR |
FIELD | fibrate | C; B + D + I + M | 256 | 5.2 | 1.05 | 288 | 5.9 | 1.18 | 0.89 | 0.75-1.05 | 0.16 |
GISSI-Prevenzione | statin | C; A + I | 120 | 5.6 | 2.77 | 136 | 6.4 | 3.15 | 0.88 | 0.71-1.15 | 0.41 |
GREACE | statin | C; A + J + L + Q + M | 112 | 12.7 | 4.24 | 180 | 25.0 | 8.33 | 0.51 |  | <0.0001 |
 diabetes substudy | statin | C; A + J + L + Q + M | 20 | 12.4 | 4.14 | 46 | 30.3 | 10.09 | 0.41 | NR | <0.0001 |
HATS | statin + niacin§§§ | R + B; D + J + M | 7 | 9.6 | 3.20 | 12 | 35.3 | 11.76 | 0.27 | NR | 0.02 |
HHS | fibrate | C; K + J + G | 56 | 2.7 | 0.55 | 84 | 4.1 | 0.83 | 0.66 | 0.08-0.53 | <0.02 |
 diabetes substudy | fibrate | C; K + J + G | 2 | 3.4 | 0.68 | 8 | 10.5 | 2.11 | 0.32 | NR | 0.19 |
HPS - MRC/BHF | statin | C; A + G | 1328 | 12.9 | 2.59 | 1507 | 14.7 | 2.94 | 0.88 | 0.81-0.94 | 0.0003 |
 diabetes substudy | statin | E + B | 601 | 20.2 | 4.20 | 748 | 25.1 | 5.22 | 0.81 | 0.19-0.30 | <0.0001 |
HPS2-THRIVE | niacin | C; G + M | 1696 | 13.2 | 3.39 | 1758 | 13.7 | 3.51 | 0.96 | 0.90-1.03 | 0.29 |
IDEAL | statin | C; G + J + O | 411 | 9.3 | 1.93 | 463 | 10.4 | 2.17 | 0.89 | 0.78-1.01 | 0.07 |
ILLUMINATE | CETP inhibitor | C; G + J + L | 464 | 6.2 | 6.16 | 373 | 5.0 | 4.95 | 1.24 | 1.09-1.44 | 0.001 |
JELIS | n-3 fatty acids | E; P; I; L; M; A | 262 | 2.8 | 0.61 | 324 | 3.5 | 0.76 | 0.81 | 0.69-0.95 | 0.01 |
LEADER | fibrate | E | 150 | 19.2 | 4.95 | 160 | 20.4 | 5.20 | 0.95 | 0.76-1.21 | 0.72 |
LIPID | statin | G | 287 | 6.4 | 1.04 | 373 | 8.3 | 1.36 | 0.77 | 0.12-0.35 | <0.001 |
LIPS | statin | C; G + J + M | 181 | 21.4 | 5.50 | 222 | 26.7 | 6.83 | 0.80 | 0.64-0.95 | 0.01 |
MEGA | statin | C; I + L + M + P | 66 | 1.7 | 0.32 | 101 | 2.5 | 0.48 | 0.67 | 0.49-0.91 | 0.01 |
ORIGIN | n-3 fatty acids | D; D + J + U; A; I; T; M + W; Q; L; Z | 574 | 9.1 | 1.47 | 581 | 9.3 | 1.50 | 0.98 | 0.87-1.10 | 0.72 |
PERFORM | antiplatelet | D; I | 1091 | 11.4 | 4.83 | 1062 | 11.1 | 4.71 | 1.03 | 0.94-1.12 | NS |
Post-CABG | statin | C; D + J + M | 207 | 30.6 | 4.08 | 271 | 40.1 | 5.35 | 0.76 | NR | 0.04 |
PREDIMED | TMD | C; D + I | 179 | 3.6 | 0.80 | 109 | 4.4 | 1.12 | 0.71 |  |  |
PROACTIVE | glitazone | C; A + J + H + M | 514 | 19.7 | 6.80 | 572 | 21.7 | 7.49 | 0.91 | 0.80-1.02 | 0.1 |
PROFIT-J | glitazone | C; A + J | 9 | 3.8 | 2.09 | 10 | 4.0 | 2.20 | 0.95 | 0.427-2.593 | 0.91 |
PROSPER | statin | C; G + J | 408 | 14.1 | 4.41 | 473 | 16.2 | 5.07 | 0.87 | 0.74-0.97 | 0.01 |
RPS | n-3 fatty acids | D | 733 | 11.7 | 2.35 | 745 | 11.9 | 2.38 | 0.99 | 0.88-1.08 | 0.64 |
SHARP | statin/ezetimibe | C; J + G + M | 526 | 11.3 | 2.31 | 619 | 13.4 | 2.73 | 0.84 | 0.74-0.94 | 0.0021 |
STABILITY | Lp-PLA2-inhibitor | C; D + J + U | 769 | 9.7 | 2.62 | 819 | 10.4 | 2.80 | 0.94 | 0.85-1.03 | 0.2 |
STENO-2 | statin/fibrate | A | 24 | 30.0 | 2.26 | 40 | 50.0 | 3.76 | 0.60 | 0.32-0.89 | 0.02 |
TNT | statin | C; G + J + O + T | 434 | 8.7 | 1.77 | 548 | 10.9 | 2.23 | 0.79 | 0.69-0.89 | <0.001 |
 diabetes substudy | statin | C; G + J + O + T | 103 | 13.7 | 2.79 | 135 | 18.0 | 3.68 | 0.76 | 0.58-0.97 | 0.026 |
VA Cooperative Study | fibrate | A + B | 22 | 8.2 | 4.56 | 30 | 11.4 | 6.31 | 0.72 | 0.43-1.22 | NR |
VA-HIT | fibrate | C; J + G | 219 | 17.3 | 3.40 | 275 | 21.7 | 4.26 | 0.80 | 0.07-0.35 | 0.006 |
 diabetes substudy | fibrate | C; J + G | 96 | 25.5 | 4.99 | 141 | 36.0 | 7.05 | 0.71 | 0.53-0.88 | 0.004 |
Total (n) | Â | Â | 16156 | Â | Â | 18445 | Â | Â | Â | Â | Â |
Mean | Â | Â | Â | 12.2 | 3.0 | Â | 14.8 | 3.6 | 0.85 | Â | Â |